Group items tagged

The intent of the FY17 ERP IDA is to solicit research to understand the magnitude and underlying mechanisms of PTE. The FY17 ERP IDA offers two levels of funding. Funding Level I is intended to support high-risk or high-gain research from Principal Investigators (PIs) at or above the level of a postdoctoral fellow (or equivalent), but below the level of Assistant Professor (or equivalent). Note that PIs submitting Funding Level I applications will be required to verify their eligibility for this award. Funding Level II is intended to support a more mature, hypothesis-driven research project. To be considered for an FY17 ERP IDA Funding Level II, the PI must be an independent investigator at or above the level of Assistant Professor (or equivalent). While not required, applications to either Funding Level I or II should provide relevant preliminary data. Preliminary data for either Funding Level may come from the PI's published work, pilot data, or from peer-reviewed literature. The requested budget level should be appropriate for the scope of research proposed.For Funding Level I:The anticipated direct costs budgeted for the entire period of performance for an FY17 ERP IDA award will not exceed $300,000. The maximum period of performance is 2 years. For Funding Level II:The anticipated direct costs budgeted for the entire period of performance for an FY17 ERP IDA award will not exceed $500,000. The maximum period of performance is 3 years. FY17 ERP IDA Focus Areas: The research impact for the FY17 ERP IDA is expected to benefit the military, Veteran, and civilian communities.

The purpose of this FOA is to bring about decreases in IPV risk factors and increases in IPV protective factors by increasing strategic data-driven planning and sustainable use of community and societal level primary prevention activities that address the social determinants of health (SDOH) and are based on the best available evidence. In addition, the FOA will help to further develop the evidence-base for community and societal-level programs and policy efforts to prevent IPV by increasing the use of evaluation and existing surveillance data at the state and local level. Another goal of the FOA is for SDVCs to support the integration of primary prevention goals and action steps throughout the state and local level IPV planning and capacity building activities. The aim of integrating primary prevention into state planning is to help states leverage diverse funding and partnerships to increase the implementation of primary prevention above and beyond DELTA funding. DELTA Impact requires SDVCs to focus on the implementation of 3 to 4 evidence-informed programs and policy efforts within three specific focus areas. SDVCs will also focus on developing or enhancing an already-existing State Action Plan (SAP) to increase the use of data for planning and the prioritization of primary prevention of IPV based on any existing health inequities within their jurisdictions. SDVCs will be expected to participate in the national evaluation of the FOA and provide leadership at the state and national level.

"This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term "complex" can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to "model" disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present announcement (R21 activity code) can be used for applications to develop early stage, high-risk, exploratory approaches or establish proof-of-concept where there is little or no preliminary data."

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this Big Data to Knowledge (BD2K) R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs.  To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development for biomedical researchers who need the requisite knowledge and skills to extract knowledge from biomedical Big Data.  To extend the reach of the course, each educational activity is required to develop open educational resources (OERs) that adhere to FAIR (findable, accessible, interoperable, and reusable) principles. Ideally, OERs should be useful to individuals at all career levels, from predoctoral students to established investigators. 

Research grants for the Secondary Analysis of Existing Alcohol Epidemiology Data Sets are intended to provide support for studies that utilize currently available data sets to increase our understanding of the incidence, prevalence and etiology of alcohol related problems and disorders in the population, as well as the risk and protective factors associated with them. Research that employs analytic techniques which demonstrate or promote methodological advances in alcohol-related epidemiologic research is also of interest.

This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase Ill and beyond) application submitted under PAR-18-117 (https://grants.nih.gov/grants/guide/pa-files/PAR-18- 117.html}. The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (http://www.nccih.nih.gov (http://www.nccih.nih.gov)).

The goal of this funding opportunity announcement is to solicit applications focused on 1) providing data enablement for the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium supported through the companion FOA (RFA-AG-18-013) and 2) sustaining and expanding the big-data infrastructure of the AMP-AD Knowledge Portal as a collaborative research platform through which members of the Consortium, researchers at large, and citizen scientists can engage in rapid translational learning and contribute to the development of predictive models of AD and AD-related dementias.

This funding opportunity announcement (FOA) seeks to support efforts focused on linking pertinent data from healthcare system records (e.g., suicide attempt events) to mortality data so that a more accurate understanding of the risk factors for, and the burden of, suicide among those seen in structured healthcare settings can be discerned.

The primary objective of this FOA is to stimulate innovative Convergent Neuroscience (CN) approaches to establish causal and/or probabilistic linkages across contiguous levels of analysis (e.g., gene, molecule, cell, circuit, system, behavior) in an explanatory model of psychopathology. In particular, applicants should focus on how specific constituent biological processes at one level of analysis contribute to quantifiable properties at other levels, either directly or as emergent phenomena.  Although not required, it is preferable that applications link at least three levels of analysis and include an emphasis on genetics. The projects under this FOA will develop novel methods, theories, and approaches through a CN team framework, bringing together highly synergistic inter/transdisciplinary teams from neuroscience and "orthogonal" fields (e.g., data/computational science, physics, engineering, mathematics, and environmental sciences). Successful teams will combine, expand upon, or develop conceptual frameworks and theoretical approaches, and build explanatory computational models that connect contiguous levels of analysis. Such frameworks, theories, and computational explanatory models should be validated through experimental approaches to elucidate biological underpinnings of complex behavioral (including cognitive and affective) outcomes in psychopathology. Additionally, a goal of this program is to advance research in CN by creating a shared community framework of resources which may be used by the broader research community to further research, as such, successful team will have robust plan for sharing data and other resources.

This Funding Opportunity Announcement (FOA) aims to stimulate the broader research community to utilize a resource funded through the American Recovery and Reinvestment Act of 2009 (Recovery Act) to generate and evaluate hypotheses about the complex interrelationships and multi-directional influences among genetics, brain maturation, neurocognitive function, and psychiatric symptoms during development. This FOA is a strategic effort to disseminate this data resource, stimulate the broader research community to use the resource, and accelerate research on neurodevelopment and trajectories of risk for mental illness. Secondary goals of this initiative are to foster collaborations among researchers from diverse fields of expertise, enhance diversity of research questions and analytic approaches, advance methods for integration across data modalities and levels of analyses (i.e., imaging, genomics, behavior), and encourage inclusion of early stage investigators among these collaborations.

The goal of this funding opportunity announcement (FOA) is to provide a global outline of areas for innovative, targeted basic behavioral and social science research and intervention development research to reduce the number of new HIV infections and improve the overall health of those living with HIV and encourage research grant applications in these areas. This FOA encourages research designed to (a) conduct basic behavioral and social science research that is needed to advance the development of HIV prevention and care interventions, (b) translate and operationalize the findings from these basic studies to develop interventions and assess their feasibility and (c) conduct tests of the efficacy of HIV prevention and care interventions. The R21 mechanism is specifically intended to encourage new exploratory and developmental research projects. These studies should break new ground or extend previous discoveries toward new directions or applications. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel methodologies, tools, technologies, or interventions that could have a major impact on health research and practice. Unlike applications under the R01 mechanism, preliminary data are not required for R21 applications. Preliminary data may nonetheless be included if available.

This funding opportunity announcement (FOA), issued by the National Institutes of Health (NIH) Office of Behavioral and Social Sciences Research (OBSSR) and participating Institutes and Centers invite Research Education Grant (R25) applications to develop, implement, evaluate and disseminate short courses in innovative methods for behavioral and social sciences research (BSSR).  Methodological domains include but are not limited to experimental design, data collection, measurement, and data analysis and visualization.

The National Institute on Drug Abuse (NIDA), in partnership with the Substance Abuse and Mental Health Services Administration (SAMHSA) is soliciting cooperative agreement applications with the intention of ultimately funding up to three research sites and one data coordinating center (DCC) to participate in the 'HEALing Communities Study': Developing and Testing an Integrated Approach to Address the Opioid Crisis. The HEALing Communities Study will test the immediate impact of implementing an integrated set of evidence-based interventions across healthcare, behavioral health, justice, and other community-based settings to prevent and treat opioid misuse and Opioid Use Disorders (OUD) within highly affected communities. Highly affected communities of interest could include counties or cities within states that are burdened with higher than average rates of overdose mortality and opioid-related morbidity, and other complications. Combined, all the communities participating in a single research site application must demonstrate having experienced at least 150 opioid related overdose fatalities in the past year, based on the most recent complete year of data available (15% of these deaths must be in rural communities). States within the top third for age-adjusted drug overdose death rates in 2016, (per the Centers for Disease Control) are of special interest. The integrated set of evidence-based prevention and treatment interventions should be designed to achieve the following goals: reduce overdose fatalities, and events; decrease the incidence of OUD; and increase the number of individuals receiving medication-assisted treatment, retained in treatment beyond 6 months, and receiving recovery support services compared to baseline.

There are 5.4 million individuals who self-identify as American Indian/Alaska Native (AI/AN) in the US, and there are 567 federally registered tribes. While characterized by many strengths and resiliencies, as a whole, AI/AN populations experience significant disparities compared to the general population across a range of health conditions and outcomes, including infant mortality, alcohol-related mortality, substance abuse, unintentional injury, homicide, suicide, depression, post-traumatic stress disorder, obesity, chronic kidney disease, asthma, diabetes, cardiovascular disease, selected cancers, and other chronic diseases. Premature death rates, while decreasing in other US racial/ethnic minority populations over the past 15 years, are increasing among AI/AN populations. However, the examination of data on AI/AN populations in aggregate may obscure the significant heterogeneity within the AI/AN population due to tribal affiliation, geographic region, and other factors. For example, gastric cancers affect AI/AN populations in different parts of the country at different rates ranging from 6.1/100,00 in the Eastern US to 24.5/100,000 in Alaska. At the same time, national survey and epidemiological studies often do not report data on AI/AN populations because the numbers are too small or AI/AN individuals are folded into the highly heterogeneous "Other" category, thus not available to interpret any health outcomes specific for AI/AN populations. For these reasons, there is a critical need to build a more comprehensive evidence base regarding the health of AI/AN populations.

The mission of the Simons Foundation Autism Research Initiative is to improve the diagnosis and treatment of autism spectrum disorders by funding, catalyzing, and driving research of the greatest quality. The program is seeking applications for SFARI awards from individuals who will conduct bold, imaginative, rigorous, and relevant research. Applications are invited for two categories of grants, including SFARI Pilot Awards and SFARI Pilot Awards. 1) SFARI Pilot Awards: These grants are intended for innovative, high-impact proposals requesting support for small-scale projects or early-stage experiments that will build on preliminary data or a prior track record and lead to competitive applications for funding by SFARI or other organizations. Investigators new to the field of autism are encouraged to apply. The maximum budget is $330,000 (including indirect costs) over two years. 2) SFARI Research Awards: Grants awarded through this category are designed for investigators with demonstrated expertise conducting compelling high-impact research on an experimental hypothesis for which, in most cases, preliminary data have already been gathered. The foundation also will consider projects focused on a central hypothesis where success depends on close collaboration between two or more labs. The initiative expects to fund proposals for a maximum of $975,000 over to three years. All applicants and key collaborators must hold a Ph.D., M.D., or equivalent degree and have a faculty position or equivalent at a college, university, medical school, or other research facility.

One of the oldest American foundations, the Russell Sage Foundation was established by Mrs. Margaret Olivia Sage in 1907 for "the improvement of social and living conditions in the United States." In pursuit of this mission, the foundation now dedicates itself to strengthening the methods, data, knowledge, and theoretical core of the social sciences as a means of diagnosing social problems and improving social policies. The foundation's program on Social Inequality supports research on the social, economic, political, and labor market consequences of rising economic inequalities in the United States. The program seeks Letters of Inquiry for investigator-initiated research projects that will broaden current understanding of the causes and consequences of rising economic inequalities. Priority will be given to projects that use innovative data or methodologies to address important questions about inequality. Examples of the kinds of topics that are of interest include, but are not limited to, economic well-being, equality of opportunity, and intergenerational mobility; the political process and the resulting policies; psychological and/or cultural change; education; labor markets; child development and child outcomes; neighborhoods and communities; families, family structure, and family formation; and other forms of inequality.

This FOA encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery.  Successful applicants will collaborate and conduct the trial within the NIH StrokeNet.  Following peer review, NINDS will prioritize trials among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support.  The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

This Research Fund is opening a call for projects in the following areas: * Protecting vulnerable populations from epidemics and catastrophes, including COVID-19: be it migrants, informal settlements, workers in the informal economy, isolated people, people with disabilities, the elderly * Improving data collection and quality in health: how can data and technology help us get out of the crisis, understand it and mitigate it? How can it inform future containment and epidemic control? * Understanding the effects of confinement and social distancing: what are the effects of confinement and social distancing on society and households? What are the mental health consequences? The social and domestic repercussions? * Early warning and preparedness: how do we re-enforce our health infrastructure and ecosystem (including medical devices and drug supply) to be better prepared and how do we protect our health workers and caregivers? * Preserving the environment and our health: connections between climate change, biodiversity loss and the origin of viral disease including socioeconomic dynamics leading to infectious disease outbreaks and sanitary crisis; Learnings from COVID-19 for mitigating future related crises in climate and biodiversity

The purpose of this funding opportunity is to incorporate social outcomes (quality of life, untreated pain, etc.) and cost effectiveness into FDA's existing model and policy analysis tool. Work resulting from this funding opportunity should provide more holistic insight into the opioid crisis and enhance decision makers' ability to propose and consider policy options. Such work will require the integration of new structural components, new data, and new analyses into the model. Given the paucity of data surrounding opioids interventions, this effort will also require studies to collect information about the costs, social outcomes, and other details associated with potential policies.

One Mind is inviting applications for its Rising Star Research Awards program, which seeks to fund early-career investigators who have demonstrated productivity and innovation in a scientific field that can be applied to the study of neuropsychiatric disorders such as anxiety, addiction, bipolar disorder, depression, posttraumatic stress, schizophrenia, traumatic brain injury, suicidality, and other serious psychiatric illnesses. To that end, grants of $300,000 over three years will be awarded in support of research proposals on any of a wide range of neuropsychiatric conditions. Studies focusing on bipolar disorder are of special interest, including applications that would advance therapeutics ranging from biomarkers to promising therapeutic modalities (e.g., neurostimulation). Examples of relevant research include those with potential to identify new biological mechanisms and therapeutic targets; develop new or refine existing models and research tools; identify or validate biomarkers; evaluate the effectiveness of therapies, including pharmaceuticals, electroceuticals, digital therapies, or cognitive and behavioral health interventions to prevent the onset of or promote recovery from neuropsychiatric disorders; characterize similarities and differences between two or more neuropsychiatric or neurotraumatic disorders to advance personalized medicine; improve understanding of how comorbid conditions such as cancer and diabetes, as well as other neurological and non-neurological disorders, interact with neuropsychiatric disorders and impact diagnosis, prognosis, and treatments; promote or restore brain health by conducting bi-directional and/or iterative translational research using existing clinical data or new data from small pilot clinical studies in combination with relevant preclinical or computational models; or advance digital health, telehealth, or other innovative approaches to increasing access to mental health care.